Torsten Falk - Publications

Neurology University of Arizona, Tucson, AZ 

20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Bartlett MJ, Flores AJ, Ye T, Smidt SI, Dollish HK, Stancati JA, Farrell DC, Parent KL, Doyle KP, Besselsen DG, Heien ML, Cowen SL, Steece-Collier K, Sherman SJ, Falk T. Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia. Experimental Neurology. 113413. PMID 32717354 DOI: 10.1016/j.expneurol.2020.113413  1
2020 Crown LM, Bartlett MJ, Wiegand JL, Eby AJ, Monroe EJ, Gies K, Wohlford L, Fell MJ, Falk T, Cowen SL. Sleep Spindles and Fragmented Sleep as Prodromal Markers in a Preclinical Model of LRRK2-G2019S Parkinson's Disease. Frontiers in Neurology. 11: 324. PMID 32477237 DOI: 10.3389/fneur.2020.00324  1
2020 Bartlett MJ, So LY, Szabò L, Skinner DP, Parent KL, Heien ML, Vanderah TW, Polt R, Sherman SJ, Falk T. Highly-selective µ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model. Bmc Research Notes. 13: 149. PMID 32164786 DOI: 10.1186/s13104-020-04994-7  1
2019 Hay M, Polt R, Heien ML, Vanderah TW, Largen-Milnes TM, Rodgers KE, Falk T, Bartlett MJ, Doyle K, Konhilas J. A Novel Angiotensin-(1-7)-glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation Related Memory Dysfunction. The Journal of Pharmacology and Experimental Therapeutics. PMID 30709867 DOI: 10.1124/jpet.118.254854  1
2018 Flores AJ, Bartlett MJ, Root BK, Parent KL, Heien ML, Porreca F, Polt R, Sherman SJ, Falk T. The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia. Neuropharmacology. 141: 260-271. PMID 30201210 DOI: 10.1016/j.neuropharm.2018.09.005  1
2018 Ye T, Bartlett MJ, Schmit MB, Sherman SJ, Falk T, Cowen SL. Ten-Hour Exposure to Low-Dose Ketamine Enhances Corticostriatal Cross-Frequency Coupling and Hippocampal Broad-Band Gamma Oscillations. Frontiers in Neural Circuits. 12: 61. PMID 30150926 DOI: 10.3389/fncir.2018.00061  1
2017 Caballero B, Sherman SJ, Falk T. Insights into the Mechanisms Involved in Protective Effects of VEGF-B in Dopaminergic Neurons. Parkinson's Disease. 2017: 4263795. PMID 28473940 DOI: 10.1155/2017/4263795  1
2016 Sherman SJ, Estevez M, Magill AB, Falk T. Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing l-DOPA-Induced Dyskinesias. Case Reports in Neurology. 8: 53-8. PMID 27293405 DOI: 10.1159/000444278  1
2015 Bartlett MJ, Joseph RM, LePoidevin LM, Parent KL, Laude ND, Lazarus LB, Heien ML, Estevez M, Sherman SJ, Falk T. Long-term effect of sub-anesthetic ketamine in reducing L-DOPA-induced dyskinesias in a preclinical model. Neuroscience Letters. PMID 26644333 DOI: 10.1016/j.neulet.2015.11.047  1
2014 Flores AJ, Bartlett MJ, So LY, Laude ND, Parent KL, Heien ML, Sherman SJ, Falk T. Differential effects of the NMDA receptor antagonist MK-801 on dopamine receptor D1- and D2-induced abnormal involuntary movements in a preclinical model. Neuroscience Letters. 564: 48-52. PMID 24525249 DOI: 10.1016/j.neulet.2014.02.004  1
2012 Mabrouk OS, Falk T, Sherman SJ, Kennedy RT, Polt R. CNS penetration of the opioid glycopeptide MMP-2200: a microdialysis study. Neuroscience Letters. 531: 99-103. PMID 23127847 DOI: 10.1016/j.neulet.2012.10.029  1
2012 Falk T, Congrove NR, Zhang S, McCourt AD, Sherman SJ, McKay BS. PEDF and VEGF-A output from human retinal pigment epithelial cells grown on novel microcarriers. Journal of Biomedicine & Biotechnology. 2012: 278932. PMID 22547925 DOI: 10.1155/2012/278932  1
2011 Yue X, Falk T, Zuniga LA, Szabò L, Porreca F, Polt R, Sherman SJ. Effects of the novel glycopeptide opioid agonist MMP-2200 in preclinical models of Parkinson's disease. Brain Research. 1413: 72-83. PMID 21840512 DOI: 10.1016/j.brainres.2011.07.038  1
2011 Falk T, Yue X, Zhang S, McCourt AD, Yee BJ, Gonzalez RT, Sherman SJ. Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease. Neuroscience Letters. 496: 43-7. PMID 21507340 DOI: 10.1016/j.neulet.2011.03.088  1
2010 Falk T, Gonzalez RT, Sherman SJ. The yin and yang of VEGF and PEDF: multifaceted neurotrophic factors and their potential in the treatment of Parkinson's Disease. International Journal of Molecular Sciences. 11: 2875-900. PMID 21152280 DOI: 10.3390/ijms11082875  1
2009 Falk T, Zhang S, Sherman SJ. Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease. Molecular Neurodegeneration. 4: 49. PMID 20003314 DOI: 10.1186/1750-1326-4-49  1
2009 Falk T, Zhang S, Sherman SJ. Pigment epithelium derived factor (PEDF) is neuroprotective in two in vitro models of Parkinson's disease. Neuroscience Letters. 458: 49-52. PMID 19442875 DOI: 10.1016/j.neulet.2009.04.018  1
2006 McKay BS, Goodman B, Falk T, Sherman SJ. Retinal pigment epithelial cell transplantation could provide trophic support in Parkinson's disease: results from an in vitro model system. Experimental Neurology. 201: 234-43. PMID 16764861 DOI: 10.1016/j.expneurol.2006.04.016  1
2006 Falk T, Zhang S, Erbe EL, Sherman SJ. Neurochemical and electrophysiological characteristics of rat striatal neurons in primary culture. The Journal of Comparative Neurology. 494: 275-89. PMID 16320238 DOI: 10.1002/cne.20819  1
2001 Falk T, Strazdas LA, Borders RS, Kilani RK, Yool AJ, Sherman SJ. A herpes simplex viral vector expressing green fluorescent protein can be used to visualize morphological changes in high-density neuronal culture. Electronic Journal of Biotechnology : Ejb. 4: 20-21. PMID 20811504  1
Show low-probability matches.